MARKET COMPOSITE
Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
CDTX - Cidara Therapeutics Inc
$2.27
-0.16(-6.58%)9:00:00 PM 2/26/2021
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop antiviral Fc-conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and Coronavirus. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Summary:

  • Volatility is at a recent 2 week low. A recent low volatility of stock movement within a box range could trigger break through when activities pick up.
  • A moving average of short volume ratio is at a recent 2 week low. A lower short volume ratio could be a bullish signal.
Stock Statistics
MarketCap100.6M
PE Ratio
PEG Ratio-0.0
P/B3.7
P/S (ttm)10.8
Earning Growth (QoQ)
Revenue Growth (QoQ)
Short %4%
Held by Institutions %65%
1 Day Vol Adjusted Return-1.0
1 Month Vol Adjusted Return-1.0
3 Month Vol Adjusted Return-0.2
6 Month Vol Adjusted Return-7.0
20 Days SMA Price ZScore-1.8
50 Days SMA Price ZScore-0.4
12 -26 Days PPO0.4
1 Month Average Short Volume Ratio46.4
1 Day Volume Change ZScore-0.4
1 Month Daily Vol5.8
Related Topics
leak data

Related Topics

Peers

Stock news

    02/25/2021CDTX
    Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results

    SAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today reported financial results for the three months and full year ended December 31, 2020 and provided an update on its corporate activities and product pipeline. “We are pleased with our progress across our rezafungin Phase 3 trials and Cloudbreak pla...

    02/17/2021CDTX
    UTILITY Therapeutics Joins Antimicrobials Working Group

    The Antimicrobials Working Group (AWG) announced today the addition of UTILITY therapeutics Ltd. (UTILITY) to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. This new addition brings AWG's membership to 13 antimicrobial drug companies.

    02/17/2021CDTX
    Cidara Therapeutics Announces New Data for Rezafungin at the 21st ICHS Symposium

    New analyses from completed Phase 2 STRIVE trial support once-weekly, long-acting rezafungin for the treatment of candidemia and invasive candidiasis in high-risk patient populationsSAN DIEGO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced data from three posters at the 21st International Immuno...

    02/11/2021CDTX
    Cidara Therapeutics to Present New Data for Rezafungin and Influenza AVCs at the 21st ICHS Symposium

    SAN DIEGO, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced an oral presentation and four poster presentations at the 21st International Immunocompromised Host Society (ICHS) Symposium on Infections in the Immunocompromised Host, taking place virtually Feb. 17-19, 2021. Cidara will share new findi...

    01/25/2021CDTX
    Cidara Therapeutics Announces Key Additions to its Board of Directors

    SAN DIEGO, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced the appointments of internationally-renowned molecular biologist Bonnie Bassler, Ph.D., and seasoned life science executive Carin Canale-Theakston to its board of directors. “We are pleased to welcome Dr. Bassler and Ms. Canale-Theakston ...

    01/14/2021CDTX
    What Kind Of Shareholders Own Cidara Therapeutics, Inc. (NASDAQ:CDTX)?

    A look at the shareholders of Cidara Therapeutics, Inc. ( NASDAQ:CDTX ) can tell us which group is most powerful...

    01/5/2021CDTX
    Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that the Compensation Committee of its Board of Directors granted a stock option to purchase 115,000 shares of its common stock to a new employee, pursuant to the Cidara Therapeutics, Inc. 2020 Inducement Incentive Plan, with a grant date...

    12/15/2020CDTX
    Cidara Therapeutics Appoints Biotechnology Industry Veteran Christopher Kurtz As Executive Vice President of Technical Operations

    Former head of commercial API manufacturing at Gilead Sciences will lead technical operations for development of Cidara’s antifungal and antiviral programsSAN DIEGO, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced the appointment of Christopher (Chris) Kurtz as executive vice president of technic...

    12/8/2020CDTX
    Is CDTX A Good Stock To Buy Now?

    Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors’ consensus returns have been exceptional. In the following paragraphs, we find out […]